Dr. Andy Smith
Life Science Professional
Valuations - current issues in biotech & pharma
Dr. Andy Smith discusses valuations of profitable biotech and pharma companies relative to history, concluding that indications show biotech is too cheap at the current time. The discussion explores the PE values of various companies and how these have changed over time.
[ close ]
Information and opinions contained in this broadcast have been compiled or arrived at by the organisation making this presentation. Any statements, information and opinions contained in this broadcast,
in particular those concerning investments and the possible or assumed future performance, costs, dividends, returns, production levels or rates, prices, reserves, divestments, growth or other trend
projections and any estimated earnings are or may be forward looking statements and as such involve risks and uncertainties. Actual results and developments may differ materially from those expressed
or implied by these statements depending on a variety of factors.
This broadcast is brought to you by 3B NEXUS who make no representation or warranty regarding the accuracy or liability or completeness of any information provided and accepts no liability for any
loss arising from the use hereof. Any reliance you place on such information will be at your sole risk.